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Abstract 
 
BACKGROUND: Hypoglycemia can be a complication of diabetic ketoacidosis (DKA) 
protocols. This prolongs time to DKA resolution, increasing hospital stay and mortality risk. 
Does a revised DKA protocol reduce the incidence of hypoglycemia and reopening of the anion 
gap due to inappropriate transition to subcutaneous insulin? There is a lack of published data in 
the U.S. on factors affecting time to resolution of DKA and LOS in the ICU. This review was 
focused on evaluation of safety outcomes and protocol effectiveness by comparing 
hypoglycemia and hypokalemia events and instances of anion gap reopening for the duration of 
DKA treatment.  
PURPOSE: To evaluate the effectiveness and safety of a diabetes ketoacidosis (DKA) protocol 
at UK Healthcare in patients with diabetes type 1: whether time to AG resolution, hypoglycemia, 
hypokalemia and anion gap reopening incidences different following transition from old protocol 
to a revised protocol. 
METHODS: Retrospective chart review of patients managed with a DKA protocol before and 
after protocol revision. Protocol efficacy was evaluated by assessing time to resolution of AG, 
length of stay (LOS) in the hospital. Protocol safety evaluated by assessing the number of 
incidences of hypoglycemic, hypokalemic events and events of anion gap reopening. 
ANALYSIS: Comparison was done using descriptive statistics as well as parametric and 
nonparametric tests to determine incidences of hypoglycemia, hypokalemia, anion gap that 
reopened, time to anion gap resolution difference of 2 protocols. Comparisons of demographic 
and clinical data of cohorts: t-test for continuous variables and the Mann-Whitney U tests.  
 
 
 
  
RESULTS: 67 patients met biochemical inclusion criteria for DKA: median ages 32 and 31 
years, 55% were males and 45% were females on average. The revised protocol (group 2, n=42) 
did not show to be safer than old algorithm (group 1, n=28) in hypoglycemia events for duration 
of the treatment with 44% (n=11) in the first group and 53% (n=22) for the second group.  It did 
not show to be safer in terms of hypokalemia, 40 % (n =10) of hypokalemia incidences in the 
first group and 50% (n=21) in the second group (p=0.458). But it showed time in to anion gap 
resolution was 3 hours faster when no hypoglycemia happened  in the second cohort compared to 
the first cohort and that the length of stay in ICU decreased by 1 day when no incidences of 
anion gap reopening happened in the second group as compared to the first cohort. The protocol 
showed to be safer for patients in terms of faster DKA resolution and shorter ICU LOS but not in 
terms of incidences of adverse events. Individual factors associate with slower resolution of 
DKA were lower admission pH (p=.029) in the first group but no correlation found in the second 
group (p=0.735). 
IMPLICATION/CONCLUSION: This project showed no difference in safety outcomes such as 
hypoglycemia or hypokalemia but improved effectiveness outcomes such as faster AG resolution 
between two groups. But it showed that increased safety (avoidance of hypoglycemia and AG 
reopening) of the protocol leads increase in effectiveness and shorter ICU LOS in the second 
group. Future studies should focus on the staff and providers compliance with following protocol 
and timely transition from IV insulin infusion to SC insulin. 
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BACKGROUND AND SIGNIFICANCE OF PROPOSED PROJECT  
 Problem Identification and Expected outcomes 
Every year, more than 100,000 patients are admitted to U.S. hospitals for diabetic 
ketoacidosis (DKA), and treatment costs exceed $1 billion (Bull et al., 2007). The mean cost of 
hospitalization is about $7,500 per stay (Fayfman et al., 2017). DKA is a serious complication of 
diabetes, which requires emergent interventions and treatments (Islam et al., 2018). DKA is a 
metabolic disorder that includes hyperglycemia with ketoacidosis caused by excessive 
production of ketones (Islam et.al., 2018). DKA protocols are designed to efficiently treat the 
condition.  Adverse events associated with the DKA treatment protocol can prolong the time it 
takes to resolve the condition. Hypoglycemia and hypokalemia are the most common 
complications of the treatment for DKA (Hirsch & Emmett, 2020). Protective strategies 
recommended against treatment complications are low-dose intravenous insulin treatment and 
thorough monitoring of potassium and blood glucose (Hirsch & Emmett, 2020). 
Hypoglycemia can prolong time to DKA resolution and increase length of hospital stay 
and mortality risk. Lorenson et al. (2019) investigated the incidence of hypoglycemia at 34 U.S. 
hospitals, and determined that 35% of patients receiving standard DKA care developed the 
condition. According to Dhatariya (2015), 28% of patients developed hypoglycemia after about 
14.7 hours of treatment. Hypoglycemia has been associated with an 85% increase in the risk of 
inpatient death, as well as a 2.5 day increase in LOS for each day of hypoglycemia (Turchin et 
al, 2009). Suboptimal compliance with the DKA protocol with regard to inadequate monitoring 
of K+ resulted in hypokalemia in a study by Kennedy et al. (2018). Two DKA protocols (old and 
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revised) at a tertiary care center in Kentucky addressed hypoglycemia and hypokalemia 
problems, and the objective of this project was to evaluate the differences in these outcomes.  
The revised DKA protocol was a hospital-wide change for which implementation began 
at the end of November 2018. As with the old protocol, the revised protocol addresses the 
problem of hypoglycemia by: 1) the addition of 5% dextrose to fluid infusion when the threshold 
for blood glucose  (BG) is < 200mg/dL, and 2) insulin infusion rate reduction by half if BG falls 
by >150mg/dL from the last BG concentration. This correlates with the American Diabetes 
Association (ADA) guideline, which directs providers to change IVF with 5% dextrose 0.45% 
NaCl at 150-250 ml/hr (Kitabchi, 2009). The revised protocol addresses hypoglycemia with 5% 
dextrose fluids when BG is less than or equal to 250mg/dL, and a 50% reduction in insulin 
infusion when BG is between 101-149 mg/dL. This simplifies the calculation step and places the 
threshold for starting 5% dextrose at an earlier point. This also follows the Joint British Diabetes 
Societies (JBDS) recommendation with the addition of glucose when blood sugar reaches 250 
mg/dL. However, the JBDS recommends adding 10% glucose rather than 5%, and at a slower 
rate of 125 ml/hr to run with 0.9% of NaCl plus KCl in order to avoid fluid overload and 
hypokalemia. According to Lorensen et al. (2019), reducing the rate of insulin infusion when 
initiating dextrose is protective against hypoglycemia. The 2009 ADA has indicated that a bolus 
of insulin is not necessary if patients receive an hourly insulin infusion of 0.14 units/kg body 
weight (equivalent to 10 units/h in a 70-kg patient), with a goal of reducing blood sugar by 50-75 
mg from the previous value every hour after beginning treatment (Kitabchi, 2009). This 
correlates with the revised protocol, which recommends the same insulin infusion rate but a 
slightly higher threshold for the blood sugar goal: 50-100 mg/dL. According to 2009 ADA 
guidelines, potassium replacement should be started when serum concentration is <5.2 to 
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maintain a level of 4-5 mEq, as patients are total body depleted despite normal or elevated serum 
results. Insulin infusion must be stopped when hypoglycemia or hypokalemia occurs (Kitabchi, 
2009). According to Fayfman et al. (2017), this can cause rebound hyperglycemia, ketogenesis 
and recurrent acidosis within about 10 minutes after abrupt cessation of insulin (half-life of 
insulin is <10 min). Consequently, hypoglycemia or hypokalemia can both prolong DKA 
resolution and increase risk of mortality due to cardiac arrhythmias and lack of BG to supply the 
cells in the body. Potassium concentrations <3.3 can lead to life-threatening arrhythmias and 
respiratory muscle weakness (Kitabchi, 2009). Also, during treatment, many patients with DKA 
do not experience adrenergic manifestations of sweating, nervousness, fatigue, hunger, and 
tachycardia—i.e., the signs and symptoms of hypoglycemia. This can lead to death; it is crucial 
to check blood sugar every hour (Fayfman et al 2017). Hypoglycemic episodes can cause 
seizures, arrhythmias and cardiovascular events. The aim of DKA protocols and guidelines is to 
resolve DKA and reduce the incidence of hypoglycemia and hypokalemia. In this project, the PI 
evaluated time to resolution of anion gap as a primary outcome and hypoglycemia (BG 
<70mg/dL), hypokalemia (K+ <3.3 mmol/L) and anion gap (AG) reopening as safety outcomes 
of a new DKA protocol at a tertiary care center in Kentucky. 
The gap in the literature is that the recommendation for DKA management is often based 
upon clinical judgment in the absence of scientific evidence. The gap in practice is the high rate of 
dangerous hypoglycemic events and AG reopening, so a tertiary care center in KY revised its DKA 
protocol to attempt to resolve these problems. This project included a thorough review of 
published, databased literature about the most common adverse events associated with DKA 
treatment protocols, such as hypoglycemia and hypokalemia. This body of literature included 
numerous randomized controlled studies as well as the currently available ADA and JBDS 
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recommendations on treatment modalities for DKA in order to facilitate faster resolution of the 
problem. The PI compared studies, appraised evidence and uncovered data from a review of the 
electronic medical record to determine incidences of hypoglycemia and hypokalemia at the tertiary 
hospital in Kentucky and analyzed the findings to determine if the current protocol was more 
effective at ensuring safe care for patients. 
Context, Scope and Consequences 
In a survey conducted in over 70 hospitals across the United Kingdom, adverse outcomes 
such as hypoglycemia occurred in 27.6% of patients undergoing DKA treatment, and 
hypokalemia in 55% of these patients (Dhatariya et al 2015). Because these adverse reactions are 
so prevalent, it is important to follow recent, evidence-based guidelines when treating DKA. 
Incidences of hypoglycemia and hypokalemia are higher when providers do not adhere to the 
ADA and the JBDS recommendations (Gupta et al.2017, Munir et al.,2017; Thuzar et al.,2014 
Dhatariya et al 2015). Also, following recommendations of the 2009 ADA guidelines yielded 
better outcomes in hypoglycemia reduction than the JBDS recommendations (Lorenson et al, 
2019). Researchers have shown that hospital and Intensive Care Unit (ICU) Length of Stay 
(LOS) are longer when DKA treatment protocols do not follow clinical guidelines (Bull, et al., 
2007; Islam et al., 2018; Ramakkishnan et al., 2013). Additionally, the literature shows that the 
time to DKA resolution is longer when non-protocolized treatment modalities or outdated 
protocols are used (Fusco et al., 2015; Islam., 2018; Laliberte et al., Ramakrishnan et al., 2013; 
Munik et al., 2017; Hara et al., 2013; Brown et al,2018).   
Centers for Disease Control (CDC) reported age-adjusted DKA hospitalizations rates 
steadily increasing from 2009 to 2014 at an average annual rate of 6.3% (Benoit et al., 2018). 
Delays in DKA resolution and hypoglycemia put patients at a higher risk for prolonged 
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hospitalization. Turchin at al. (2009) showed statistically significant increases in LOS and patient 
death for every day of hypoglycemia. Longer term problems identified with poor blood sugar 
control included kidney failure, cardiovascular problems, vision problems and stroke (McCary, 
2018).  
Evidence-Based Interventions 
Despite available literature and multiple studies recommendation and the 2009 ADA 
guideline consensus statement, it is not clear which protocol is best for DKA management, 
because DKA protocols are based on clinical judgment rather than scientific evidence. DKA 
protocol therapy is aimed at correcting hypovolemia, hyperglycemia, metabolic acidosis and 
electrolyte imbalances (Bull et al., 2007).  This project is important because of the lack of clear 
studies in this area, and the numerous problems during DKA treatment such as high incidences 
of adverse effects and a lack of consensus on standards of care among providers. 
The revised protocol at this medical center was simplified, and the Primary Investigator 
(PI) evaluated how efficient the protocol was to reach faster AG resolution and to avoid most 
common complications, such as hypoglycemia and hypokalemia. The PI reviewed the hospital's 
DKA protocol, compared it with recommendations from the literature, and highlighted the main 
changes from the previous protocol. The new protocol has only two fluid options rather than 
eight (isotonic 0.9% NaCl and 5% Dextrose 0.45% NaCl), which makes it more practical to use.  
Also, it specifies K+ replacement before the start of the protocol, which correlates with the ADA 
recommendation to replace K+ to reach at least 3.3 mmol/L before starting the insulin and a goal 
to maintain K+ between 4-5 mmol/L. The change to the electrolyte replacement part of the 
protocol (from premixed electrolytes and IV fluids to an electrolyte replacement sliding scale) 
simplified the electrolyte replacement process and made it easier to keep K+ at goal. The old 
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protocol required electrolytes to be premixed with IV fluids before treatment by the pharmacist 
resulting in the need for constant IV fluid bags changes. The change eliminated possible 
interruptions in treatment continuation caused by fluid bags not being readily available on the 
ward. The multi-step insulin-dosing algorithm was modified to a two-step table with simplified 
calculations on titration adjustments. The new protocol is easier to follow for the staff as its 
instructions are clearer, simpler to follow and less time consuming, especially for the nurses who 
are assigned higher acuity patients.  
            The first stage of the revised DKA protocol specifies titration adjustments when 
BG >250 with the goal of a 50-100mg/hr BG decline and electrolyte replacement based on 
biochemical profiles. The second stage: specifies IV fluids and insulin titrations if BG < or 250 
with the goal of a 150-250 BG concentration. IV fluids are adjusted based on BG and serum 
sodium concentration thresholds. Two types of IV fluids are isotonic 0.9% solution in the first 
stage and 5% dextrose 0.45% NaCl in the second stage. When BG concentration reaches less 
than 250 mg/dL then the IV fluids from the second stage are started. The ADA guidelines 
recommended the fluid change after intravascular volume is restored and sodium (Na+) 
concentration is normal (135mEq or >) or elevated, and addition of dextrose when BG reaches 
200mg/dL with the goal that BG be >200 mg/dL. The revised protocol addressed Na+ correction 
with 0.9% NaCL infusion (when corrected Na+ less than 135) or 0.45% NaCl (when corrected 
Na+ more of equal to 135). Recent evidence showed that the outcome is not different when 
continuous insulin infusion at rate of 0.14 units/kg/hr administered without bolus versus adding 
bolus for faster blood sugar correction. Also, the literature recommends insulin infusion 
continuation until ketoacidosis resolved, with serum BG < 200mg/dL and AG closure based on 
the laboratory ranges of the individual facilities; and switch to subcutaneous (SC) insulin 
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coverage after DKA resolution and 1-2 hours before infusion stopped (Hirsh & Emmet, 2018). 
Current DKA protocol have only continuous insulin infusion without insulin bolus and have 
references on when to switch to SC insulin and insulin drip discontinuation follows the most 
available recent recommendation. The new protocol addresses the ADA’s goals for hypokalemia 
and hypoglycemia prevention and uses the same fluid modalities and strategies for electrolyte 
replacement, insulin infusion titration and monitoring as the ADA guideline. 
 Objectives/Purpose 
The purpose of this project was to evaluate outcomes of currently used treatments for 
hyperglycemic crisis in patients with type 1 diabetes and DKA. 
Objective 1: First, to investigate the use of a new DKA protocol at tertiary care center in 
KY in decreasing the number of hypoglycemic episodes.  
Objective 2: Secondly, to investigate the number of episodes of hypokalemia that 
occurred with the revised protocol and compare that to the number of episodes associated with 
the old protocol.  
Objective 3: Finally, to investigate whether the revised DKA could close the AG sooner 
than the old protocol.  
The revised protocol, designed for use with adult patients with DKA, came into effect on 
November 28, 2018 at the tertiary hospital. The PI evaluated whether outcomes improved, and 
hypokalemia and hypoglycemia episodes decreased six months after and six months prior to 
implementation of the new protocol.  Outcomes evaluated included the timeline to AG closure 
timelines and blood sugar resolution (from time of insulin infusion start to first BG<250mg/dL, 
and AG < or = 16 mEq/L).  
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Theoretical Framework 
The Framework for Continual Improvement of Health Care emphasizes continued 
nursing education and by its application it is possible to define practice problems that can lead to 
solving them (Batalden & Stoltz, 1995, see Appendix G).  
In order to achieve medical advances and continue to improve practice, nurses must 
combine knowledge with professional experience. For example, it is crucial to know anatomy 
and microbiology, and to understand the nursing discipline and its values. Because of concerns 
about the quality and efficacy of a protocol nurses must work with other health care disciplines 
to make continual improvements.  
 Continual improvement involves a team approach. For instance, nurses working at their 
best cannot meet their goal without the pharmacists working at their best as well. A single 
department meeting their improvement goals is not enough; the whole healthcare team must be 
involved in order to achieve lasting change. Leaders have to help workers understand the system 
to facilitate this teamwork.  
Variation or defect of event need to be understood in order to properly respond to the 
problems. Is it common or special variation? Is AG resolution time increasing because of a 
common variation, such as a faulty protocol that requires fundamental change in the process? Or 
it is a special variation, such as provider’s non-adherence to the protocol or a late transition from 
IV to SC insulin? By removing special causes or fixing common variations, improvements can 
be made. Leaders must understand the psychology of change in order to help their followers 
achieve it. Finally, the theory of knowledge involves the combination of an action with a theory. 
If hypothesis about the cause of the problem or variation and attempted solution to the variation 
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are close to actual response or desired outcomes, then the treatment is probably effective, and 
this project evaluation is testing if the treatment of DKA is effective (Batalden & Stoltz, 1995). 
Synthesis of the Evidence in the Literature 
Diabetes ketoacidosis (DKA) is an acute complication of diabetes with increased 
production and decreased clearance of serum ketones due to uncontrolled hyperglycemia. 
Patients are severely dehydrated and develop metabolic acidosis. The PICOT question was: In 
adults 18 years and older, how do evidence-based DKA treatment protocols based on recent 
guidelines predict DKA resolution during a hospital stay, compared to DKA treatments that are 
not based on guidelines?  
The search started with a thorough review of the most recent articles about recommended 
treatments for DKA, other conditions that can lead to metabolic acidosis and monitoring 
standards to DKA resolution. The databases searched included PubMed, Ovid, National Medical 
Library, CINAHL with Full Text, EMBASE, BMJ Clinical Evidence, Medline and UpToDate 
system. Search terms included: DKA, hyperglycemic crisis, DKA protocol, diabetes 
management, with narrowing to diabetic ketoacidosis, diabetic emergencies, hyperglycemic 
emergencies searches to find information specific for insulin infusion treatments of DKA. The 
search resulted in the selection of 15 articles from 2007 to 2019 and the ADA guidelines and the 
JBDS. About 50% of the searched literature includes articles published between 2017 and 2018. 
Eleven articles were evidence from guidelines developed from systematic reviews or evidence 
from well-designed cohort studies, and the rest of the articles were quality improvement, 
descriptive survey, and review designs. The search did not yield many randomized controlled 
trials design studies to answer the PICOT question, so cohort studies were mostly the only 
evidence to evaluate the practice. 
 
 
14 
 
 Evidence-Based Recommendations 
The PI reviewed the literature focusing on treatment modalities and its outcomes, such as 
a timeline for correction of ketoacidosis as well as safety indicators such as episodes of 
hypoglycemia and hypokalemia.  
According to the ADA, DKA diagnosis defined when BG > 250mg/dl, presence of 
ketones in serums or urine and pH < 7.3 or bicarbonate < or= 18.0 mmol/L. The JBDS (2013) 
recommends protocolized management of DKA, including fluid repletion with 0.9% NaCl as 
initial IV fluids and aiming for ketone clearance with a weight-based fixed rate insulin IV drip 
(Phillips & Sinha, 2018). The guideline states to infuse fluids within 24-36 hours and complete 
half of those IV fluids within 8-12 hours of admission to correct dehydration (Islam et. al., 2018). 
Bicarbonate administration is not recommended for metabolic acidosis correction unless pH <6.9 
(Islam et al. 2018). Discontinuation of IV insulin should happen 2-4 hours after subcutaneous 
(SC) insulin administration to avoid rebound hyperglycemia (Kitabchi, 2009). The ADA noted a 
six-fold increase in the rate of hypoglycemia occurrence with the use of intensive insulin therapy 
in medical ICU patients (n=1200) are not recommended except surgical ICU patient population 
(Moghissi et al., 2009). Boluses of IV insulin, tight glycemic control and fixed rates are 
considered intensive insulin therapies as referenced in the literature. When a patient is treated 
with regular insulin, a starting threshold of glucose concentration should be ≤180 mg/dl. IV 
insulin therapy should be kept at goal of 140 and 180 mg/dL from the time it is initiated and 
targets <110 not recommended in critically ill patients in order to prevent hypoglycemia 
(Moghissi et al., 2009).  
The two-bag protocol is the addition of 10% dextrose IV fluids to a NaCl solution rather 
than using one bag with only NaCl isotonic solution throughout the whole DKA treatment time. 
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This has been associated with faster hyperglycemia resolution and reduction in hospital and ICU 
LOS by more than 20%. Using boluses in aiding faster hyperglycemia correction did not show any 
differences in time for DKA resolution (Islam et al., 2018). In a randomized controlled study, 
Brown et al. (2018) evaluated the effect of an insulin bolus compared to no bolus on the 
management of DKA. They noted no difference in time to DKA resolution between the two 
groups, no increase in incidences of hypoglycemia (no statistically significant findings) and no 
difference in hospital LOS. Brown et al's study had a low sample size (n=145) and the potential 
for inaccurate record keeping. One conclusion from this study is that it is safer to use the protocol 
without insulin boluses because it has no benefit in faster resolution, but it can theoretically 
increase the risk of hypoglycemic events.  
Evidence-Based Protocol 
In a randomized controlled study (RCS), Turchin et al. (2009; n=2582) found that 
hypoglycemia occurs in an average of 8% of all admissions, and is strongly linked to increased 
LOS and risk of mortality. The 2006 ADA guidelines recommended that the DKA drip include 
an insulin bolus in addition to the fixed-rate insulin infusion, and this could have contributed to 
an increase in hypoglycemia incidences. Hypoglycemia episodes were reduced when the insulin 
infusion was titrated based on the 2009 ADA guidelines (Lorenson et al., 2019, Gupta et al., 
2016, Thuzar et al., 2014).  Laliberte et al., (2017) noted no difference in hypoglycemia rates 
with insulin infusion adjustments with bolus insulin administration as compared to insulin 
titration without bolus. Conversely, a RCS by Thuzar et al. (2014) showed faster DKA 
resolution, shorter LOS, and fewer hypoglycemic and hypokalemic events (p<0.05) by titration 
of the IV insulin with a goal of BG between 160 to 250 mg/dl, addition of 10% dextrose 
(100ml/hr) when BG reached 250 mg/dl or less, and replacement of K+ when serum K+ was less 
 
 
16 
 
than 5.  In their large RCS (n=256), Hara et al. (2013) noted a nine hour decrease in time to DKA 
resolution with a similar treatment to the one used by Thuzar et al. (2014). However, they did not 
find the difference in safety outcomes, such as reduction of hypoglycemia and hypokalemia, 
compared to the treatment without protocol (p<0.05). Choosing the right IV fluids is important 
for better efficacy and safety outcomes. In their RCS, Munir et al. (2017; n=383) evaluated 
outcomes of one bag versus two bag protocols and noted clinically significant results, such as 
faster AG closure and BG resolution and fewer hypoglycemia episodes with the two bag 
protocol.  
The protocol can be an effective tool to manage DKA and following the protocol closely 
can improve outcomes, as the following studies show. Researchers have found that compared to 
no protocol, DKA protocols yield faster DKA resolution (Bull et al., 2007; Ramakrishana et al., 
2013; Thuzar et al., 2014); reduce rebound DKA episodes (Ramakrishana et al., 2013), and 
significantly reduce hypoglycemia and hypokalemia (Thuzar et al., 2014). A QI study (n=30) by 
Kennedy (2018) showed that suboptimal compliance with the DKA protocol led to hypokalemia 
(n=8). Ronsley et al. (2017; n=157) also noted low compliance in their study on a pediatric 
population. Hence, better outcomes were related to protocol adherence.  
Finally, in a large national study, Dhatariya et al. (2015; n=281) gathered data on DKA 
management in 72 hospitals across the UK. They reported mixed findings, suggesting that the 
fixed rate of insulin infusion could be too aggressive, resulting in increased hypoglycemia rates. 
It was also confounding if high rates of hypokalemia and hypoglycemia were due to poor 
adherence or faulty guidelines. The study evaluated DKA management with 70% of providers 
following JBDS guidelines. The researchers noted 28% of patients receiving the DKA protocol 
developed hypoglycemia with a median time of development at 15 hours after treatment started. 
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They also found that 55% of patients receiving the DKA protocol developed hypokalemia 
(Dhatariya et al., 2015).  
In conclusion, the literature review revealed that DKA treatments based on the 2006 
ADA guidelines cause high rates of hypoglycemia and hypokalemia, but researchers have noted 
mixed results with the 2009 ADA guidelines as well. The rates of hypoglycemia and 
hypokalemia are also prevalent with DKA treatment based on the JBDS guidelines. The review 
revealed inconclusive results with regard to safety outcomes, and this could result from faulty 
guidelines or poor adherence.  Hence, there are no clear recommendations for providers. 
However, resolution outcomes related to DKA seem to be better with slow insulin titration, and 
with the right type of IV fluids (2 bag protocol over 1 bag protocol), based on biochemical 
markers and electrolyte replacement to maintain BG and K+ at safe and steady levels. There is a 
need to constantly evaluate outcomes and compare protocols to find the best possible evidence to 
achieve better patient results. With these findings in mind, the PI chose to evaluate the variables 
of time to AG resolution, AG reopening, hypokalemia, and hypoglycemia to better understand 
the efficiency of the current protocol in use at the medical center in Kentucky. 
Agency Description 
Setting 
The project focused on outcome evaluation of a DKA protocol at UK HealthCare in 
Lexington Kentucky. The project focused on UK HealthCare Hospital, which is a 945-bed 
medical center. It is a Level 1 Trauma center with approximately 40,000 patient visits to the ED 
each year. The hospital serves Fayette and surrounding counties, with the largest population from 
Eastern Kentucky (UK HealthCare). This organization is comprised of 9,000 healthcare 
professionals, including physicians, nurses, pharmacists and other providers. 
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The project involved the collection of data from all inpatient wards that treat patients with 
DKA, including progressive units, ICUs and the ED. Registered nurses work closely with 
advanced care providers, physicians and nursing care technicians to deliver critical care to DKA 
patients. Critical care trained nurses can autonomously manage hyperglycemia crises with the 
help of protocols. Care is provided continuously, 24 hours a day. Each unit can have its own 
specific care guidelines in addition to the hospital-wide guidelines. Critical care units at UK 
Chandler Hospital include cardiothoracic vascular intensive care unit, a clinical decision unit, 
emergency and trauma services, medical intensive care units, progressive care units, and the 
stroke center. There are 206 critical care beds at UK Healthcare that make up cardiothoracic, 
medical, surgical, neurosciences and compose the setting for this project. 
Target Population and Recruitment 
UK Chandler Medical Center provides health care to all Kentucky counties. UK 
HealthCare discharged 37,789 patients in 2016 (UK HealthCare, 2016). The target population for 
this study was adults with type 1 diabetes who were admitted to the hospital with DKA as their 
primary diagnosis and received DKA protocol treatment. The diagnosis of DKA is based on 
ADA biomarker concentration obtained from venous blood gas and a serum chemistry panel 
(Menchine, 2011). For safety outcome evaluation, the PI included a comparison of number of 
episodes of hypoglycemia (blood sugar less than 70 mg/dL) and hypokalemia (potassium less 
than 3.3 mEq/L; Kitabchi, et. al., 2008) and efficacy of the protocol was evaluated through 
calculation of duration in hours for AG to reach 16 or less and calculation of duration of BG to 
reach 250mg/dL. Other variables evaluated were admission pH <7.3 to determine relation to AG 
closure. 
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The PI collected laboratory values and demographic data through retrospective chart 
reviews six months before November 28, 2018 (revised DKA protocol implementation day) and 
six months after this day. According to data collected using the REDCap research informatics 
tool, six months before November 28, the sample population included 25 subjects; six months 
after implementation of the revised protocol, there were 42 subjects, for a total of 67 individuals.  
The inclusion criteria were patients with diabetes mellitus type 1 (DM1). The exclusion 
records of subjects included conditions such as DM2, uncompensated liver failure, 
uncompensated kidney failure, myocardial infarction, fluid overload or severe impairment of a 
vital organ during protocol examination days; pregnancy; and children under the age of 18 years. 
Also, the PI excluded patients admitted to the hospital who used non-insulin treatments to treat 
hyperglycemia and alcohol in their blood. The reason for exclusion was that all of the listed 
problems could lead to erroneous interpretation of relevant laboratory results.  
Alignment with Organizational Goals 
The organization's mission corresponds with that of this project, specifically, to look for 
cutting edge services on the level of the best providers in the nation, and lead the way to ensure 
quality, safety and value for every patient. The protocol could be an effective way to resolve 
DKA, or the project could produce new data so that any deficiencies can be improved. Also, the 
project can lead to further studies to improve the protocol, encourage additional training, and to 
encourage other researchers to work on improving knowledge about DKA treatment. The project 
aligned with a strategic plan to reduce patients’ LOS and hence improve their experiences. So, 
the actions to correct the problems can be developed with future studies that can result in a 
reduction in a patient stay and bettering the quality of care and patient experiences. The strategic 
plan addresses patient care by potentially limiting high-cost patient care expenses for treating the 
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sickest. This means expansion of ambulatory patient care and a higher number of healthier 
patients. DKA patients require emergent treatment and are included in the category of the sickest 
patients. Additionally, UK HealthCare reported 810 patients on insulin for treatment of DKA and 
non-DKA hyperglycemia who experienced hypoglycemia (blood sugar < 51) in 2018, and the 
goal is to lower this number. If complications such as hypoglycemia can be avoided with an 
efficient protocol, this can reduce the sickest patients’ expenses. This project served as 
knowledge tool that indicated how well the DKA protocol aligns with the ADA guidelines and 
the JBSG. This project was designed to support the academic role of the organization to advance 
research and adopt evidence-based practices.  
Stakeholders 
There were multiple stakeholders or people who would be interested in protocol 
evaluation.  The primary stakeholders were nurses, nurses' techs and patients because they were 
the targets of the efforts.  Nurses implemented the DKA protocol and adjusted DKA treatments 
based on MDs’ or other providers’ orders. NCTs were charting intake and output and checking 
BG hourly. There were secondary stakeholders as well: medical doctors, advanced care 
providers, nurse managers, and pharmacists who were directly responsible for reviewing orders 
and adjusting orders based on biochemical results. Other key stakeholders included senior 
clinical experts, Critical Care Services Councils, policy makers (those who sit on the committees 
to approve the protocol), those who can influence others (CEOs) and those with academic or 
research interests (Community ToolBox). These last groups of stakeholders were remotely 
involved in the process of DKA implementation but were mostly working on safety 
improvement and necessary changes to the DKA protocol at the population level. 
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Facilitators and Barriers 
 Facilitators helped this evaluation project to be conducted efficiently.  They involved 
leadership support, IRB approval, and hospital mission alignment with the project goals and 
outcomes.  One of the main facilitating factors was the persistence of the evaluator and unfolding 
results. But the biggest facilitator was that this protocol was already used hospital-wide; and it 
was a change that need to be evaluated for effectiveness. The stakeholders who used the protocol 
were interested to know if what they were implementing was actually working. Some barriers 
included delays in data retrieval, staff shortage to retrieve the data, other research projects, and 
technical problems.     
Design 
The PI used a retrospective cohort design for the chart review.  This design was chosen 
because chart evaluation involved comparison of sample groups available in records. 
Retrospective chart reviews were used to see the outcomes of the protocol before it was revised, 
for the time between 2018-05-28 and 2018-11-28 and after the change, for dates between 2018-
11-28 and 2019-05-28.  
Methods 
Project Interventions 
This project involved the collection of data from patient charts and included all inpatient 
areas that treat patients with DKA, such as progressive care units, ICUs, and the ED. The study 
includes only data extraction and interpretation without any intervention. Old and revised DKA 
protocols were compared with the review of stored data, and outcomes of DKA treatments were 
evaluated, such as episodes of hypoglycemia, hypokalemia, and the timeline for correction of 
AG.   
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IRB and Ethical Concerns 
A letter of approval was received from the Nursing Research Council on June 12, 2019. 
IRB approval was obtained on 10/2/2019 (#53236) in order to access the patients’ information. 
After IRB approval, the PI reviewed patients’ extracted data done by CCTS with variables of 
interest. CCTS practices and rules of compliance with HIPAA ensured the protection of 
participants’ health information. It was not practical to obtain consent because the PI was doing a 
fully retrospective EMR review. This project was granted exempt status because the PI used de-
identified data of the patients’ records and the project was not defined as clinical research, so 
consent was not required. The PI was not required to submit a waiver of authorization for 
approval of data extraction, as data was de-identified by CCTS. The study did not include any 
prospective data; therefore, there was no access to patients and no opportunity to seek informed 
consent. The application was approved by IRB and a nonmedical type exemption was granted. 
The risk to patients was minimal and did not pose any additional threat than the other 
ethically reviewed studies. The only possible risk for the study was a breach of personal 
information due to unforeseen breaches of privacy. The only people that had access to the data 
were the University of Kentucky IRB, CCTS specialists, a statistician and the PI. This data for 
this study will be kept for six years and the destruction of all research data will be done per UK 
HealthCare policy. After IRB approval, the PI reviewed patients’ extracted data with variables of 
interest. 
The CCTS data extractor uploaded the data into REDCap. About two weeks after the 
request was submitted the PI received an email that included a link to access the data. The data 
were released to the PI in de-identified format. The PI did not make any attempt to identify the 
subjects.  
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The PI compared old and revised DKA protocols with the review of stored data, 
evaluated outcomes of DKA treatments such as episodes of hypoglycemia, hypokalemia, and 
timeline for correction of AG before change for the time between 2018-05-28 and 2018-11-28 
and after change for dates between 2018-11-28 and 2019-05-28. Data collection included: 
demographics (race, gender, age, ethnicity), length of ICU and non-ICU stay, lab values (venous 
blood pH, K+, BG values, AG), LOS, admission disposition, discharge disposition. 
  Sample 
The sample population included adult patients with diabetes type 1 as their primary 
diagnosis for admission who received DKA protocol treatment at the Medical Center. The PI 
chose convenience sampling because it was a review of all the patients' charts over a period of 6 
months before and after the set date. The number of patients selected for chart review happened 
to be at the hospital during the time period and were not randomly assigned. No other hospitals' 
protocols were evaluated. The PI evaluated the difference between the "exposed" cohort (the 
charts of patients treated with the revised protocol) and the "unexposed" cohort (the charts of 
those treated with the old protocol).  Two samples had an unequal number of participants.  
The information collected included adults aged 18 and older, of both sexes, and the 
sample population includes 25 and 42 patients in each group respectively. It excluded records of 
subjects less than 18 years old, as well as cases with other conditions, such as uncompensated 
liver failure, uncompensated kidney failure and evidence of alcohol intoxication because of the 
possibility of data interpretation errors. Minors and pregnant women were excluded because of 
variations in variables characteristics that can compromise laboratory results interpretation. The 
sample evaluated was similar to the general population of patients with DKA, with the exclusion 
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of conditions that can affect a proper evaluation of ketoacidosis resolution but no other 
comorbidities. 
Measures and Instruments. Implementation. Data Collection 
The PI relied solely on objective data of biochemical tests that make my project valid. 
Specifically, the PI examined patient outcomes by measuring a number of episodes of ↓BG (BG 
<70 dL), ↓K (hypokalemia, K < 3.3) and timeline for AG closure (<16 mmol/L) and timeline to 
BG resolution of 250 dL or less.   
After data collection was completed by CCTS technicians, the PI reviewed the data and 
further excluded cases based on DKA treatment noncompliance or misleading data when 
laboratory values such as glucose were collected at longer than a 1-hour interval. This was 
viewed as treating the patient with modalities other than the protocol, or as the use of a different 
treatment to resolve DKA. Therefore, the excluded cases were identified and not counted in 
statistical analysis. SPSS software was used to compare the data of two different protocols using 
descriptive and inferential statistics and displayed the results of the findings with the help of 
tables.  After the findings interpretation, the results were shared with members of the project 
committee. 
Physical resources needed for chart review included a personal computer, since all patient 
information was stored in electronic health records. The International Statistical Classification of 
Disease and Related Health problems, 10th revision (ICD-10) was used to classify and code all 
diagnoses for inclusion and exclusion criteria. Diagnosis search from 2019 ICD-10-CM included 
code E10.10 (type 1 diabetes mellitus with ketoacidosis without coma). Admission type was 
"emergency," because patients admitted to emergency are sent to other units when a bed 
becomes available. So, the patients either stayed in the ED or transferred to subsequent units for 
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treatment continuation. Exclusion criteria for the search included diagnosis coded as Z33, Z34, 
Z3A (pregnant state) and K76.6 (decompensated alcoholic cirrhosis), R74.0 (lactic acidosis), 
F10, (ingestion of drugs such as aspirin, methanol, ethylene glycol) and T45 (advanced chronic 
kidney disease). 
Data analysis 
The PI compared the number of episodes of hypoglycemia, hypokalemia and an average 
time to AG closure in both sample groups from the time of hospital admission until AG 
resolution. This was based on biochemical results, and the PI used descriptive statistics (means 
and standard deviations or frequency distributions) to summarize study variables. Using SPSS 
software, the PI analyzed data and compared study variables with a two-sample t-test, chi-square 
test of association or Mann-Whitney U test. All data analysis was conducted using SPSS, version 
24 with an alpha level of .05.  
Descriptive statistics were used to translate the characteristics of the sample into 
measurable numerical data. AG resolution was counted as the serum AG reaching 16 or less 
mmol/L. The PI compared number of patients, age, race, gender, glucose, adverse incidences of 
low potassium and pH levels to evaluate differences in both groups at baseline and throughout 
the timeframe of DKA treatment. 
Results (demographics and findings) 
Cohort 1 or group 1 included all patients who received treatment before the protocol 
change and cohort 2 or group 2 included all patients who received treatment after the protocol 
change occurred. 
A higher proportion of patients were Caucasian compared to cohort 2 (92% vs. 74%, 
p=.032). The majority of patients were in their early 30s (mean 32 vs. 31, p=.830). The 
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progressive care unit was the most frequently admitted service with 48% for the patients in 
cohort 1 and 52% in cohort 2 (p=.300). The average number of days spent in the hospital for 
treatment of DKA with the old protocol was 5 days (p=.472), 3.5 with the new protocol, and 2 
days in the ICU in both cohorts (p=.656). 
In general, AG reopening was not associated with longer overall stay in the hospital 
(p=.96). AG reopened in about 28% of patients in both cohorts and hypoglycemia episodes noted 
for the overall duration of hospital stay were more than 96%, vs 93% in the first and second 
groups respectively. Hypoglycemia that happened on the DKA drip before AG closure was 
slightly higher in the 2nd group than in the 1st group, with 29% vs 24% (p=.683), so the revised 
protocol did not result in fewer hypoglycemic episodes. But the rate of hypoglycemia on the 
DKA drip for the duration of IV insulin infusion almost doubled in both groups (24%->44%-> 
and 29%->53%; p=.510). This may indicate that the patients were on the insulin drip after AG 
closure, and this resulted in large increase in hypoglycemic episodes. Data suggest that the 
transition to SC insulin was not timely.  
Instances of hypokalemia were 40% in the 1st cohort and 50% in the second cohort 
(p=.427). So, the revised protocol showed higher number of hypokalemic episodes, suggesting 
that a sliding scale for K+ replacement could have resulted in more autonomy for the staff, but 
also higher noncompliance either among providers or staff. 
As compared to literature findings, hypoglycemia and hypokalemia rates were higher at 
this medical center than what was found in the literature. For example, the rate of hypokalemia 
was 28.6% (p=.038), and the rate of hypoglycemia was 8.6 % (p=.036) in the study by Thuzar et 
al., (2014). Hara et al. (2013) had a 30.1% rate of hypokalemia (p=.413) and an 8% rate of 
hypoglycemia (p=.259).  
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Time to resolution of AG was 11.8 hours in the 1st group and 10.43 hours in the 2nd group 
(p=.219), time to blood sugar resolution on average was 6.6 hours (1st group) vs 6.5 hours (2nd 
group) in both cohorts (p=.883). Time to AG resolution was close to findings noted in the 
literature. Patients treated with the 2009 ADA consensus statement protocol, had 13.6 hours for 
DKA to resolve (n=113, p<.01) in Hara et al., study (2013) and 15 hours to DKA resolution 
(n=35, p=.01), in Thuzar et al., study (2014). 
For the adverse events and associated ICU LOS analysis, there was no significant 
difference (p=0.643) when adverse events occurred (AG reopened) and when treatment had no 
adverse events (as measured by ICU LOS) in the first group (n=25). For adverse event of AG 
reopening in relation to ICU LOS, there was 3 ICU days on average when no event happened 
and 4 ICU days when such event occurred. The AG reopening in this sample did not indicate 
longer ICU stay (in days), compared to the cases when no AG reopening happened.  For the 
second group (n=42), there was a significant difference (p=.031) between incidences of AG 
reopening and ICU length of stay (as measured by ICU LOS). In particular, the mean length of 
ICU stays for patients whose AG reopened was 4 days compared to 2 days for patients who had 
no instances of AG reopening. The AG reopening in this sample indicated longer ICU stay (in 
days), on average, compared to the cases with no AG reopening. More patients required ICU 
level of care in the second group 40.5 %, compared to the first group 30.8 % (p=.333) 
Problem resolution analysis showed that in the first group of patients (n=25), the time to 
AG resolution was not much different (11.5 vs 11.89 hours) when hypoglycemia episodes 
occurred versus when there were no occurrences of hypoglycemia. There was no difference 
between the timeline for AG resolution and hypoglycemia before AG closure (p=0.847) for the 
first cohort. For the second cohort (n=42), the PI concluded that in those cases with no instances 
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of hypoglycemia before AG resolution resulted in faster AG resolution, and this was statistically 
significant (p=0.05). The majority of cases in the second cohort (n=30) had on average 9 hours to 
AG resolution when there were no hypoglycemic episodes before AG closure. When 
hypoglycemia did occur, the time to AG resolution increased by almost 4 hours, for a total of 13 
hours.  
Also, there was positive moderate association between incidences of pH less than 7.3 and 
AG resolution for the first group, n=25 (Spearman’s rho .436, p=.029). But no association was 
found between incidences of pH less than 7.3 and time to AG resolution in the second group, 
n=42 (Spearman’s rho .055, p=.735) 
Discussion  
There was no significant difference in hypoglycemia episodes between cohorts. 
Hypoglycemia episodes while on the protocol before AG closure were 24% for the first cohort 
and 29% for the second cohort, with more patients in second cohort (p=.683). Interestingly, 
patients had 96% and 92% of hypoglycemia episodes in the first and second groups throughout 
the whole time spent in the hospital. This suggests that the protocol change did not result in a 
smaller number of hypoglycemia episodes, and hypoglycemia rates were high for the duration of 
the entire hospital stay. The study showed that hypoglycemia events between both groups were 
not different for the first objective of the project. 
The second objective was satisfied by calculating the number of hypokalemia episodes 
that were higher in the 2nd cohort (40% vs 50%) but there was no statistically significant 
difference between groups (p=.427). 
Finally, for the third objective, AG resolution in hours was almost 2 hours faster in the 
2nd group, (12 vs 10 hours; p=.22). AG closure was not related to hypoglycemia episodes within 
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AG resolution in the second cohort (p=.847). It showed that the first cohort had 12 hours on 
average for AG to close when no episodes of hypoglycemia occurred. However, there was faster 
AG resolution in the second group when no hypoglycemia occurred during treatment before AG 
closure (p=.05). Hypoglycemia incidences affected time to AG closure in the second cohort 
(n=30), which was statistically significant. On average, it took 9 hours for the AG to close. Also, 
in the second group, length of ICU stay was twice as long when AG reopened during the hospital 
stay (p=.031). So, avoidance of hypoglycemia and AG reopening can help with faster problem 
resolution and fewer days spent in the ICU.  
Also, instances where venous pH was less than 7.3 were higher in the second cohort 64% 
(n=16) and 75% (n=30; p=.343) were not statistically different between the two groups. But a 
moderate positive association between low pH and time to treatment resolution was found. It 
means an association between lower pH and longer time to treatment resolution (p=.029), when 
no such association was found in the second group (p=.735). That can suggest that low pH was 
attributed to other conditions rather than ketoacidosis, possibly affecting the laboratory values.   
Limitations and Strength of the study 
Small sample size was a significant limitation of this study. Sample size could increase if 
the observation timeframe for both cohorts was broadened, but due to time constraints it was not 
possible to achieve.  
The number of people in both cohorts were not equal.  There was a smaller sample size 
than anticipated. Future studies could be done to evaluate compliance with the protocol 
adherence among providers and staff as well as to evaluate comorbidities. Another study could 
survey nurses about their attitudes about the protocol and provide feedback for improvement. 
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The strength of the study is that there is no known DKA protocol treatment evaluation 
study done at UK HealthCare. 
Implications for practice, education, policy, and future research 
Future studies should focus on hypoglycemia and AG reopening reduction as those 
preventive strategies have been shown to promote faster AG resolution and shorter ICU LOS. The 
next study can focus on a larger sample and employ a two-year timeframe for evaluation before 
and after the revised protocol with inclusion of prospective study design; this should help to better 
clarify the differences in protocols.  The incidences of medication errors during drip infusion were 
not evaluated in this study; future researchers could focus on that, since it can influence the 
effectiveness of the treatment.  
The protocol addressed hypoglycemia with low-dose insulin infusion without bolus and 
addition of dextrose to IV fluids when blood sugar reached less than 250mg/dL. This follows the 
2009 ADA guidelines, but there were no improvements in hypoglycemia cases between the two 
groups. This raises questions about whether other factors may be affecting high rates of 
hypoglycemia, such as staff nonadherence, and the need for accountability when following the 
protocol. These factors should be evaluated in future studies. Also, the time from AG closure to 
transition from DKA insulin drip to sliding scale can be evaluated because it can affect 
hypoglycemia outcomes. Since, the results suggested long time to transition to SC insulin after 
AG resolution occurred. A system alert is needed to notify the providers when AG closure occurs, 
and it could be done by the pharmacists to reduce hypoglycemia with a timely transition to SC 
insulin. These alerts can be a valuable tool and an important protective strategy since this 
institution is a teaching hospital and many junior providers might not be aware of the specifics of 
DKA management. Finally, future studies can focus on ways to reduce hypoglycemia, regardless 
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of insulin drip infusion or sliding scale use. This number is very high throughout the hospital stay, 
and on average occurs almost on every patient who is affected by diabetes.  
Potassium replacement orders should be easily available for the nurses, with clear 
instructions to start replacing potassium when values are between 4.1-5 or less than 4.1. There is 
a need for a timely K+ replacements.  It can be achieved by timely notifications or call back from 
lab personnel to alert nursing. Also, pharmacists can verify orders for K+ replacement sooner.  
Instructions about potassium K+ replacement and doses parameters should be included on the 
algorithm in the same table next to IV fluids and IV insulin titration for better visualization. 
Proactive, timely potassium replacement can help prevent hypokalemia, pauses in insulin drip 
infusion and AG reopening. 
Further research can evaluate the sustainability of the DKA protocol. In the next study, 
researchers can examine costs and mortality numbers and compare those numbers after every 2 
years of protocol implementation. 
Summary/Conclusion 
Outdated evidence-based DKA treatment modalities can lead to high numbers of adverse 
outcomes. New evidence-based practices become available with time and there is a need to 
implement that in the current practice. 
This project was a retrospective review to assess the effectiveness and safety of the 
currently used protocol in order to see what can be done to implement better protocols in the 
future. There was no improvement in safety outcomes noted, such as less hypoglycemia or 
hypokalemia, but the project did reveal better effectiveness outcomes, such as faster AG closure 
timelines. However, the study noted that increased safety of the protocol can increase its 
effectiveness and shorter ICU LOS. The study showed that AG resolution was on average 9 
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hours when no hypoglycemia occurred, and it was about 4 hours faster than when hypoglycemia 
occurred in the second sample group. Also, ICU LOS was two times shorter when incidences of 
AG reopening did not happen in the second group. Biochemical results with lower pH were 
related to longer AG resolution in the first group.  
Since AG reopening was shown to significantly increase ICU LOS, strategies focused on 
hypoglycemia rebound hyperglycemia, and hypokalemia should be explored since all of these 
factors can cause AG reopening. Also, diabetic educators should be alerted when the lab values 
are hitting or approaching critical values so as to actively participate in DKA management 
teaching and helping staff and providers to understand the specifics of treatment. The review 
revealed that labs to determine ketones in the blood serum were inconsistently ordered. The 
majority of the providers ordered this laboratory on admission, and then very few ordered follow 
up on ketone disappearance.  
The study didn’t find that the revised protocol is less effective than the old algorithm. 
Even though no improvements in safety outcomes were noted, there was faster DKA resolution, 
which is consistent with other researchers’ findings on effects of the 2009 guidelines-based 
protocols. Looking back at theoretical framework, the variation can be caused by special 
circumstances, such as providers being unaware of the best time to transition to SC insulin, and 
responding to this problem could reduce incidences of hypoglycemia. Also, nurses and 
laboratory staff should work together to ensure more timely potassium monitoring, as well as 
proactive and timely replacement. 
Neither adherence to the protocol nor medical errors were evaluated in this project, and 
should be evaluated in the next studies. Looking back at theoretical framework, the project 
yielded valuable information and this information should be brought to the attention of the 
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committee that is working on revision of the protocol so they can take these findings into 
consideration. Strategies to avoid hypoglycemia and hypokalemia should combine knowledge of 
DKA management as well as knowledge of the system, communicating and working with 
providers, pharmacists, diabetic educators and nursing in order to explore possible solution for 
improvement in safety outcomes. All three objectives were met as the number of hypoglycemic 
and hypokalemic episodes was evaluated, as well as time to AG closure. 
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Appendix A: Old DKA Algorithm  
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Appendix B: Old DKA Algorithm ( IVFluids Titration) 
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Appendix C: Revised DKA Protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STAGE 1 Insulin IV Fluid + Electrolyte Management 
If BG decreases > 101 mg/dL, within 1 
hour (From last FSBS) 
Decrease current infusion rate by 50%  
(Multiply current rate by 0.5) 
Fluid per physician order 
 
For electrolyte replacement, use Electrolyte 
Replacement Protocol if ordered. If not ordered contact 
provider to get replacement orders as electrolyte values 
result in SCM. 
 
 
If BG decreases 50-100 mg/dL, within 1 
hour (From last FSBS) 
Continue current infusion rate 
If there is any increase in BG or if BG 
decreases < 49 mg/dL, within 1 hour 
(From last FSBS) 
Increase current infusion rate by 50% 
(Multiply current rate by 1.5) 
 
Check BG every 1 hour. Follow titration table 
Stage 2 – Begin when BG < 250 mg/Dl (for BG 250 mg/dL and lower); Target glucose during stage 2 is 150-250 mg/Dl.  Activate order for stage 2 insulin, Initiate 
D5W-0.45% NaCl  @ 100 ml/hr and discontinue all other IV fluids ordered with Stage 1 of DKA/HHS treatment. Continue electrolyte replacement described above.  
 
 
Stage 1 – Begin when BG > 250 mg/dL (For BG 251 mg/dL and higher) 
Nursing guideline gNU-27 Adult DKA and HHS Guideline: ICU, ED and Progressive Use Only 
*Orders may 
change based on 
provider 
discretion 
 
Do NOT start insulin infusion if initial K ≤ 3.3 mEq/L, implement replacement per Electrolyte Replacement Protocol or notify provider for potassium orders AND  
regarding delay in starting insulin infusion. 
Insulin and Fluid Titration 
Initial DKA Insulin Infusion Rate: 0.14 unit/kg/hr (maximum: 14 units/hr) – Use DKA Insulin setting on Alaris® Pump 
Check BG every 1 hour. Follow titration table 
STAGE 2 Insulin IV Fluid (Titrate hourly)  
If BG > 250 mg/dL, within 1 hour Follow Stage 1 titration guidelines above. 
Increase current infusion rate by 50%  
(Multiply current rate by 1.5) 
Restart previous IV fluids from Stage 1 at 250 ml/hr 
D/C all D5W-containing  IV fluids 
If BG 150-250 mg/dL, within 1 hour Continue current infusion rate 
 
Continue or initiate D5W-0.45% NaCl at current rate 
(Initial rate 100 ml/hr) 
If BG 101-149 mg/dL, within 1 hour Decrease current infusion rate by 50% 
(Multiply current rate by 0.5) 
Increase D5W-0.45% NaCl by 50 ml/hr 
May increase x3 to max rate of 250 ml/hr 
Notify provider when 250 ml/hr is reached 
If BG 70-100 mg/dL, within 1 hour Decrease current infusion rate by 50% 
(Multiply current rate by 0.5, recheck BG in 30 minutes) 
Increase D5W-0.45% NaCl by 50 ml/hr 
May increase x3 to max rate of 250 ml/hr 
Notify provider when 250 ml/hr is reached 
If BG <70 mg/dL 
 
 
 
 
STOP insulin infusion. Give 25 g of dextrose 50% per 
hypoglycemia management protocol, notify provider. 
 
 
When BG > 100 mg/dL, restart insulin infusion at 50% 
previous rate (multiply previous rate by 0.5). 
Adjust D5W-0.45% NaCl to infuse at 250 ml/hr and notify 
provider 
 
 
When BG > 100 mg/dl, continue D5W-0.45% NaCl at 250 
ml/hr.  
 
 
Stage 3 - Transition to subQ insulin per provider order. Turn off insulin infusion 2 hours after first dose of subQ insulin. IVFs at the discretion of the provider. 
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Table 1: Synthesis of the Literature 
 
Autho
r, 
YEA
R 
Study Design  
 
Purpose 
Sample 
Characteristics & 
Setting 
Variables: 
Independent 
Dependent 
Data Analysis Main Findings 
1.Bull 
et al., 
2007 
Design:  RCS  
Purpose: to  
determine the 
effect of a 
mandatory 
protocol for 
treating 
diabetic 
ketoacidosis  
 
Sample:  
N= 241 (btw 2000-
2005)  
IG= 111(postprotocol) 
CG=130 (preprotocol) 
Jan 1, 2000- Dec 31, 
2002 (preprotocol), and 
Jun 1, 2003-Dec 31, 
2004 (postprotocol), 
with a principal DKA 
diagnoses)  
Setting: 
University-affiliated 
U.S. public teaching 
hospital  
 
IV= the 
protocol 
DV1= ICU 
LOS 
DV2= hospital 
LOS 
DV3=time to 
correction of 
AG and ketone 
clearance 
DV4=#hypogly
cemic episodes 
 
Power analysis for this outcome performed 
before beginning the study and use of a two-
sided test with an alpha of .05 and a power of 
85%. Two groups compared using Student’s 
t-test from SPSS version 12.0 (SPSS, 
Chicago, IL) for Windows; p  .05 was 
considered to be significant.  
 
Before protocol implementation, the mean SD ICU 
and hospital LOS were 44 and 28 hrs and 91 and 73 
hrs. After implementation, ICU and hospital LOS ↓ 
23% and 30%, to 34 and 18 hrs and 64 and 41 
hrs, (both p < .007). Time to AG closure ↓  (both p 
< .05. Number of hypoglycemic episodes- no 
difference observed.  
 
 
 
2.Gup
ta et 
al., 
2016 
Design: RCS  
Purpose: 
to assess the 
efficacy of a 
unified 
hyperglycemia 
and DKA 
insulin 
infusion 
protocol, 
based on an 
algorithm 
aimed at 
glycemic 
targets and 
minimizing 
hypoglycemia 
 
Sample: N=62 
Surgical care 
implementation project 
n=20; 
MICU n=42 
 
Settings: Saint Louis 
University Hospital 
(SLUH) 
 
IV: insulin 
infusion 
protocol 
DV:  blood 
glucose 
numbers 
M data analyzed by t-tests or ANOVA. post-
hoc analysis was performed by the Fisher 
LSD procedure for subgroup analysis. 
Correlation and regression analysis was 
performed using Pearson’s correlation 
coefficient. Statistics on proportions were 
performed by Chi square analysis. 
Statistical procedures performed with 
Statistica for Windows (Version 5, Statsoft 
Inc., Tulsa OK). Significance was defined as 
a P < 0.05 by two-tailed testing  
 
BG targets of 100–180 mg/dL in majority patient 
population. No episodes of hypoglycemia blood  4–
6 weeks. The two year pre-institution of the 
protocol, # of hypoglycemic events ↓ (BG 
<70MG/dL pre-protocol 2.87% vs post-protocol 
2.30% < 0.001 ( statistically significant) 
3.Fusc
o et al 
2015 
Design: RCS 
for the 
treatment of 
DKA between 
July 1, 2007 
and June 30, 
2010  
Purpose: 
determine if 
treatment of 
DKA in 
MICU 
patients was 
consistent 
with the 2006 
ADA 
Guidelines  
 
   
  
Sample:  N=60 
(satisfying guidelines 
n=12; not satisfying 
guidelines n=48) 
Setting:  
University of Maryland 
Medical Center MICU 
 
IV: Diabetes 
CG 
DV1: IVF 
DV2: insulin 
gtt rate 
DV2: transition 
to SC insulin 
DV3: # rebound 
DKA, # 
hypoglycemia 
Descriptive statistics: demographic 
information. Nominal data analyzed based on 
the sample size using the chi-square test 
and Fisher Exact test. Two-sample 
student’s t-tests were used to evaluate 
differences between 2 groups for continuous 
discrete data. The Mann-Whitney U test -
evaluate differences between groups for 
nonparametric discrete data. Statistical 
analysis using StatPlus 2009 (AnalystSoft, 
Alexandria,VA). A two-sided p-value of 
<0.05 statistically significant  
 
Low compliance with the 2006 ADA CG: Sixteen 
(26.7%) patients were treated in compliance CG 
with IVF infused. 10 (83.3%) out of 12 (by CG) 
patients were appropriately transitioned to SC 
insulin from insulin gtt vs 22 (45.8%) out of 48 (not 
treated by CG) were transitioned to SC insulin from 
an insulin gtt (p = 0.045). 5 (41.6%) of patients 
treated by CG experienced an episode of rebound 
DKA compared to 11 (22.6%) patients not treated 
by CG  (p = 0.342).  
 
4.Isla
m et 
al 
2018 
Design: 
Review 
Purpose: to 
review 
Sample: N=NA  
Setting: NA 
IV=NA 
DV-NA 
MEDLINE (via 
PubMed), 
NA treated with protocol -resolution of DKA in10 h. 
After protocols-> ICU LOS ↓ 23% to 34+/18 h. M 
hospital LOS ↓ 30% to 64+/41 h. Initial bolus 
dose of insulin-> no significant benefit to DKA 
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previous 
guidelines, 
choice of 
therapy, cost, 
need for 
change to 
existing 
protocols to ↑   
efficacy of 
DKA 
treatment, ↓   
complications 
and ↓ 
economic 
burden of 
DKA  
 
 EMBASE 
searched (1 Jan 
2000- 31 Dec 
2017) by1 
reviewer using 
terms 
“Management 
of DKA”, 
“Guidelines for 
DKA” 
“Cost/Burden 
of DKA”.  
 
patients. K excretion impaired in patients with renal 
injury, K supplementation and insulin dose 
adjustment needed in CKD patients. AG closure 
earlier (10 h) with “two bag protocol” compared to 
“one bag protocol” (14 h). Hyperglycemia 
resolution faster in “two bag protocol” (7 h) 
compared to “one bag protocol” (9 h)  
 
5.Lali
berte 
et al., 
2017 
Design:  RCS 
patients with 
DKA admitted 
to the MICU. 
pre-order set 
(PRE) 
compared to 
post-order set 
(POST)  
 Purpose:  To 
determine 
compliance to 
the 2006 and 
2009 ADA 
DKA 
guidelines  
 
Sample: compliance 
with 2006 guidelines 
group: PRE n=12 (60 
total); POST n=14 (55 
total). Compliance with 
2009 guidelines group: 
PRE-order n=19 (60 
total); POST-order n=36 
(55 total) 
Setting: MICU at a 
large academic medical 
center  
 
 
IV1: PRE- 
2006 CG 
IV2: POST 
2009 CG 
DV1a: 24 h 
volume in ml, 
mean (PRE-) 
DV2a: 24 h 
IVF ml M 
(POST) 
DV1b: 
hypoglycemia, 
(%) (PRE) 
DV2b: 
hypoglycemia 
(%) (POST) 
DV1c: time to 
DKA resolution 
in h, M (IQR) 
(PRE) 
DV2c: time to 
DKA resolution 
in hours, M 
(IQR) (POST) 
DV1d: receipt 
of insulin bolus 
(PRE and 
POST) 
DV2d: insulin 
gtt M (PRE& 
POST) 
Hypothesized ↑ compliance to 50%, 52 
patients required, a power of 90% and a two-
sided a level of 0.05. Descriptive statistics -
demographic information and individual 
outcome measures, IVF, insulin 
administration and compliance rates. 
Continuous variables - Student’s t-test or 
Wilcoxon signed-rank test. The chi-square 
or Mantel–Haenszel test was utilized for 
categorical variables. To control for 
confounding, a multivariate analysis 
performed with a logistic regression model. 
Statistical analyses performed utilizing 
GraphPad Prism (GraphPad San Diego, CA, 
USA).  
 
 
 
  20% in the PRE group received treatment 
compliant with the 2006  and 25.5% in the POST 
group Compliance to the 2009 CG was 
significantly ↑ in the POST group (31.7% vs 
65.5%, OR 4.44 95% CI 1.8 to 10.92, P = 0.0004). 
Time to DKA resolution ↓ (P = 0.04), and 
hypoglycemia↑ (P = 0.0022). Only 20% of patients 
received treatment compliant with the guidelines. 
DKA treatment in the POST group was 4.44 times 
more compliant to the 2009 ADA DKA guidelines 
(contain the most updated recommendations in the 
US for the care of patients with hyperglycemic 
crises. Also, significantly ↑ compliance to 24-h IVF, 
initial insulin gtt rate, time to DKA resolution and 
appropriate transition to SC insulin in the POST 
group. Limitations: small sample size, 
confounding variables not assessed 
 
 
Autho
r, 
YEA
R 
Study Design  
 
Purpose 
Sample 
Characteristics & 
Setting 
Variables: 
Independent 
Dependent 
Data Analysis Main Findings 
 
6.Ken
nedy 
et al 
(2018) 
Study design: 
QI 
Purpose: to 
assess 
knowledge and 
confidence of 
trainee doctors 
in DKA 
management 
and adherence 
to DKA 
protocol 
Sample N=30 
patients admitted 
btw Oct 2016-Oct 
2017 
Setting: Large 
tertiary University 
teaching hospital 
IV: DKA protocol 
DV1: knowledge and 
attitudes 
DV1: fluid 
resuscitation 
DV3: adequate 
monitoring of 
potassium 
Descriptive statistics with univariate 
analysis  
Suboptimal compliance with DKA protocol with 
respect to fluid resuscitation, adequate monitoring 
of K+, with subsequent development of 
hypokalemia in 8 patients 
 
 
7.Ron
sley et 
Study design: 
RCS September 
2008- 
December 2013 
Sample N= 157  
Setting: University 
of British Columbia 
Children's Hospital 
IV: DKA protocol 
DV1: initial lab 
values 
Log-linear regression analysis with 
SAS/STAT Software version 9.4. 
Health care providers' adherence to the DKA 
protocol is poor, poor adherence to protocol’s 
IVF. The length of time on insulin infusion was 21.5 
and 24.1 hours in pediatrics 
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al 
2017 
Purpose: to 
review 
adherence to a 
provincial DKA 
protocol and the 
length time on 
an insulin 
infusion 
 
 
DV2: insulin 
infusion duration 
DV3: lab values with 
therapy 
 
8.Turc
hin et 
al 
2009 
Study design: 
RCS 
Purpose: if 
hypoglycemia 
associated with 
mortality in 
diabetic 
patients  
 
Sample: N=2582 
Setting: 734-bed 
teaching hospital 
IV= # of days with 
hypoglycemia 
DV1= hospital 
mortality 
DV2= LOS 
Frequencies, proportions, means, SD, 
median ranges; 
Summary stats for pt. demographics' 
Wilcoxon test (# days and mortality, 
LOS continuous variables); Fisher's 
exact test for binary var.; logistic 
regression for inpatient death 
probability; SAS stat. software 
Hypoglycemia was observed in 7.7% of 
admissions. Hypoglycemia was associated with an 
increase of 85.3% in the odds of inpatient death 
(P = 0.009) and 65.8% (P = 0.0003) within 1 year 
from discharge. LOS increased by 2.5 days for 
each day with hypoglycemia (P < 0.0001) 
 
 
 
 
9.Ram
akrish
nan et 
al., 
2013 
 
 
 
 
Study design: 
RCS 
Purpose: to 
analyze the 
impact of the 
standardized 
order set on the 
management of 
patients with 
DKA  
 
 
 
 
Sample : N= 165 
(Oct 2005-Nov 
2012):  
before(n=80),  
after (n=85), the 
date of introduction 
order set (Oct 2009) 
Setting: MICU 
 
 
 
IV: 'Critical Care 
DKA Protocol' 
DV1: time to achieve 
AG closure 
DV2: # of 
hypoglycemia 
episodes 
DV3: time to attain 
blood glucose level 
of 200 mg/dL 
DV4: LOS in ICU 
 
Following outcomes were compared 
between the two groups using unpaired 
t test: 1. Time needed to achieve AG 
closure, 2. Time needed to attain a BG 
of 200 mg/dl, 3. LOS in ICU solely for 
the purpose of management of DKA, 4. # 
of hypoglycemic episodes. Not 
statistically significant 
 
The time to achieve AG closure (p = 0.036) and # of 
hypoglycemic episodes (p = 0.014) significantly 
lower in group 2. The time to attain BG level of 200 
mg/dl and LOS in ICU were also lower in group 2 
as compared to group 1, no stat. sig 
The EHR-based ‘Critical Care DKA Protocol’ was 
more effective than the conventional method of 
insulin titration  
10.Mu
nir et 
al 
2017 
 
Study Design: 
RCS from 
2008-2015 
Purpose: 
compared the 
conventional 
‘one-bag 
protocol’ of 
management of 
diabetic 
ketoacidosis 
(DKA) with the 
‘two-bag 
protocol’  
Sample: N=383: 
one-bag treatment 
n= 249 
two-bag n=134 
Setting: Riverside 
University Health 
System Medical 
Center 
IV: one bag DKA 
treatment 
IV2: two bags DKA 
treatment 
DV1= AG closure 
(resolution of DKA) 
DV2= BG 
<250mg/dL 
DV3= time to reach 
HCO3 > 18 mmol/L 
DV4= LOS 
Two-independent samples t-test for 
continuous variables and χ2 test for 
proportions for categorical variables 
Outcome measures comparing the 1-bag 
vs 2-bag protocols used to compare the 
time to AG closure (primary outcome 
measure) and time to reach BG 
<250 mg/dL, time to reach HCO3 level 
>18 mmol/L, and hospital LOS 
(secondary outcome measures). 
The relationship between the time to AG 
closure and admission variables assessed 
using Pearson product–moment 
correlation. ANCOVA using AG closure 
time as the DV, and admission variables 
as covariates: patient’s age, weight, BMI, 
admission pH and AG, BHB, BUN, Cr, 
BG, HgbA1c, and the Charlson 
Comorbidity Index. Data entered into a 
Microsoft Excel spreadsheet and 
analyzed using SAS V.9.3. 
 
The AG closed in 13.56 hours in the 1-bag group vs 
10.94 hours in the 2-bag group (p value <0.0002). 
the 2-bag system favored earlier AG closure. BG 
levels improved to <250 mg/dL earlier with 2-bag 
protocol (9.14 vs 7.82 hours, p=0.0241). The 
incidence of hypoglycemic events was significantly 
less frequent with 2-bag protocol compared with 
the standard 1-bag system (1.49% vs 8.43%, 
p=0.0064).  
Author, 
YEAR 
Study Design  
 
Purpose 
Sample 
Characteristi
cs & Setting 
Variables: 
Independent 
Dependent 
Data Analysis Main Findings 
 
11.Thuzar et 
al., 2014 
Study design: 
RCS 
Purpose: to 
analyze whether 
using a 
standardized 
protocol 
improves clinical 
outcomes in the 
acute 
management of 
DKA 
Sample: 
N=71 (Jan 
2008-Mar 
2012) 
protocol group 
n=35 (Jan 
2010-Mar 
2012) 
control group 
n=36 (Jan 
2008-Dec 
2009) 
IV: DKA 
protocol 
DV: incidence of 
hypoglycemia 
(protocol vs 
control) 
DV2= incidence 
of hypokalemia 
(protocol vs 
control) 
DV3:M to 
normalize serum 
Data compared using two-tailed 
Student's  t  -test, Chi-square and 
Mann–Whitney  U  tests as applicable. 
Quantitative data were expressed as 
mean ± SD. 
 
the protocol group had significantly shorter 
mean time taken to normalize serum 
bicarbonate (15.1 h in protocol vs. 24.6 h in 
control) (  P  = 0.01), and mean length of 
hospitalization (37.9 h vs. 49.2 h) (  P  = 0.01).  
The protocol group took 11.4 h less than the 
control group ( P  = 0.05). Incidence of 
hypokalemia and hypoglycemia were 
significantly lower in the protocol group; 28.6% 
in the protocol group vs. 52.8% in the control 
group for hypokalemia (P  = 0.038), and 8.6% in 
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 Setting: a 
tertiary  
Townsville 
teaching 
hospital in 
Australia 
bicarb (protocol 
vs control) 
the protocol group vs. 28% in the control group for 
hypoglycemia ( P  = 0.036).  
 
12.Hara et al., 
2013 
Study design: 
RCS 
Purpose evaluate 
the efficacy and 
safety of protocol 
based upon the 
2009 American 
Diabetes 
Association 
(ADA) 
consensus 
statement 
 
Sample: 
N=256: 
nonprotocol n 
=143; 
protocol 
n=113 
Setting: 
University 
Medical 
Center of 
Southern 
Nevada 
IV= DKA 
protocol 
DV1= time to 
resolution of 
DKA or HHS 
DV2= LOS in 
the ICU 
DV2=LOS in the 
hospital 
Protocol efficacy -time to resolution of 
DKA or HHS, LOS in the ICU, and LOS 
in the hospital. Protocol safety evaluated 
for hypoglycemic and hypokalemic 
events 
 
Patients on the hyperglycemic crises protocol 
experienced a 9.2 hour (95% confidence interval 
(CI): 4.70-13.70; P<.001) decrease in time to 
resolution, with nonprotocol patients ,no 
difference in safety outcomes, including the 
number of patients with moderate 
hypoglycemia  
 Protocol decreased times to resolution of DKA 
without increasing the rate of hypoglycemia or 
hypokalemia 
 
13.Brown et 
al., 2018 
 
Study design: 
RCS ( Sep 1, 
2014-Jun 30, 
2016)  
Purpose: to 
evaluate the 
effect of an 
insulin bolus, as 
compared to no 
bolus, on the 
management of 
DKA.  
 
Sample: 
N=145 Bolus 
group n=58, 
no bolus 
group n=87 
Setting: 
Grady 
Memorial 
Hospital, 953 
bed academic 
medical center  
IV: DKA 
protocol 
DV1: DKA 
resolution 
variables 
(BG<200, 
pH>7.3, AG 
<12mEq, 
Bicarb>15 mEq) 
DV2: time to 
resolution 
variables, 
Incidence of 
hypoglycemia, 
incidences of 
hypokalemia  
M , range: continuous variables. 
Characteristics btw groups comparison: 
Fisher's exact test for categorical 
variable; non-parametric test: Wilcoxon 
Rank Sum Test for continuous 
variables. The Shapiro-Wilk test: to test 
mortality; 0.05 sig. level;SAS 9.4 
time to resolution of DKA from emergency 
department admission did not differ 
significantly between the insulin bolus and no 
bolus group (15 vs. 15.9 h, respectively; p = 
0.24). no difference in the secondary outcome, 
time to resolution of DKA from insulin 
infusion initiation between the insulin bolus, 
and no bolus group (10.8 vs. 11.3 h, 
respectively; p = 0.97). Receiving an insulin 
bolus did not result in a higher incidence of 
hypoglycemia (p = 0.64) or hypokalemia (p = 
0.65) within 4 h of DKA protocol initiation. No 
difference in length of hospital stay (p = 0.27) 
or survival to hospital discharge (p = 0.40) was 
observed  
Limitations: non-randomized cohort design, 
assignments by provider preference, confounding 
variables not ruled out. Potential for inaccurate 
record keeping, missing data, possibility of 
resolution to occur prior to labs collected, not 
ruled out 
 
14.Dhatariya 
(2015) 
 
Design: 
Descriptive 
study/research 
problem: survey 
method 
Purpose: to 
conduct national 
survey on DKA 
management and 
compare them 
against national 
standards with 
JBDS guidelines 
Sample: 
N=281 
Setting: 72 
hospitals at 
UK (May 1, 
2014- Nov 30, 
2014 
IV: JBDS 
guidelines 
DV: JBDS 
compliance 
(biochemistries 
relevant to DKA 
resolutions, 
recommendation 
adherence) 
Descriptive statistics (mean, SD)  
Surveys of providers (yes, no) with 
questions to determine compliance 
(biochemistries, DKA resolution) with 
JBDS; 
SPSS software 
27.6% of patients developing overt 
hypoglycemia at median time of 14.7 h after 
treatment was started. possible that currently used 
insulin drip regimen is too aggressive when BG 
drop. Unclear if the development of low K and 
BG levels is due to the poor adherence to the 
CG vs CG are wrong.  
Limitation: voluntary contribution of teams, no 
direct review of medical records, inability to 
verify accuracy of information.  
 
 
15. Lorenson et 
al., (2019) 
 
Design: RCS 
Purpose: to 
evaluate 
hypoglycemia 
episodes 
reduction in adult 
DKA treatment 
differ with fixed 
insulin protocol 
Sample=155 
Cohort 1 n=77 
Cohort 2 n= 
78 
Setting: in 
423 bed 
hospital, on 38 
bed MICU 
IV1: fixed rate 
insulin infusion 
DKA protocol 
IV2: rate-
reduction when 
initiating 
dextrose protocol 
DV: 
hypoglycemia, 
LOS, AG 
Logistic regression -incidence of 
hypoglycemia difference of 2 protocols); 
Multiple regressionincidence of  severe 
hypoglycemia, administration of D50W, 
rebound hyperglycemia) Continuous 
outcomes : ordinary linear regression 
(LOS in ICU, time to AG<or=12, time 
until serum bicarbonate > or=15, serum 
glucose prior to hypoglycemia, etc).  t-
test for continuous variables (age and 
Hypoglycaemia was 19.2% in cohort 2 ver- sus 
32.5% in cohort 1; use of dextrose 50% in water 
(D50W) was also reduced in cohort 2. No 
differences were seen in AG or bicarbonate 
correction, rebound hyperglycaemia or ICU 
length of stay.  
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Appendix B Model for Evidence-Based Practice Change 
 
 
 
 
 
 
 
Table 2: Comparison of time to resolution and adverse outcomes between cohorts. Descriptive 
statistics was used for each variable of interest 
 
 Variable n=25 Protocol # 1 
Mean (SD) 
n=42 Protocol # 2 
Mean (SD) 
p value 
Time for AG to close (in 
hours) 
11.8 (4.23) 10.43 (4.46) .22 
Time for glucose to 
normalize (in hours)  
6.6(2.31) 
  
6.5 (2.88) 
  
.883 
  
Protocol #1 (before change), Protocol #2 (after change) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vs empiric 
insulin rate  
resolution 
timeframe 
BMI) and Fisher's exact test for discrete 
variables (gender, race and 
comorbidities) 
R statistical software 3.3 
LEGEND: ↓ –  Decrease; ↑ – Increase; ; CG – Control Group; CI – Confidence Interval; DV – Dependent Variable; IG – Intervention Group; PG-
placebo group IHMR – In-Hospital Mortality Rates; IV – Independent Variable; LOS – Length of Stay; M – Mean; RCS – Retrospective Cohort 
Study; RCT – Randomized Controlled Trial;  SD – Standard Deviation; SPSS – Statistical Package for Social Sciences, ICU-intensive care unit, 
AG-anion gap, DKA-Diabetic Ketoacidosis, IVF-intravenous fluids, BG- blood glucose, ADA-American Diabetes Association, CG- clinical 
guideline, SC-subcutaneous, gtt-infusion/drip, K- potassium, Na-Sodium, CKD-chronic kidney disease, QI- quality improvement, BUN- blood urea 
nitrogen, Cr- creatinine, JBDS- Joint British Diabetes Society 
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Table 3: Comparison of demographic and clinical characteristics between cohorts 
Variable Cohort 1 (n =25) 
Cohort 2 
(n =42) p 
Age, Mean (SD) 32 (13) 31 (11) .830 
Gender, n (%) 
Male 
Female 
 
14(56%) 
11 (44%) 
 
23 (55%) 
19 (46%)  
.921 
Race, n (%) 
 
Af. American 
Other 
Caucasian  
 
 
2 (8%) 
0 (0%) 
23 (92%)  
 
 
8 (19%) 
3 (7%) 
31 (74%) 
.032 
Service, n (%) 
 
Pulmonary ICU 
PCU 
Other  
 
 
8 (32%) 
12(48%) 
5(20%)  
 
 
17 (41%) 
22 (52%) 
3 (7%)  
.300 
Discharge disposition 
 
Home 
Other 
  
 
19(76%) 
6 (24%) 
 
35(83%) 
7 (17%)  
.434 
Hospital LOS, 
median (IQR) in days 5 (9.5) 3.5 (9) .472 
ICU LOS, median 
(IQR) in days 2(4.5) 2 (4) .656 
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Table 4: Comparison of adverse outcomes between cohorts 
 Variable Cohort 1 (n=25) n (%)  
Cohort 2 
(n=42) n (%)  
p 
Incidences of 
AG reopening 
 
 
7 (28%) 
 
 
12 (29 %) 
 
 
 
.960 
 
Hypoglycemia 
Yes 
  
Hypokalemia 
Yes 
 
24 (96%) 
 
 
 
10 (40%)  
 
39 (93%) 
 
 
 
21 (50%)  
 
.599 
 
 
 
.343 
Hypoglycemia for 
duration DKA drip 
treatment before AG 
closed 
6(24%) 12 (29%) .683 
Hypoglycemia for 
duration of DKA drip 
treatment  
11 (44%) 22 (53%) .510 
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Table 5: Comparison of treatment resolution within each group based on blood sugar  
Independent sample T test 
 
 
  Cohort 1 (n=25) 
Mean (SD) 
P Cohort 2 (n=42) 
Mean (SD) 
P 
Time to AG resolution 
(in hours) when 
hypoglycemia 
occurred within AG 
resolution timeframe 
  
Yes (n=6)  
11.50(3.39) 
No 
(n=19) 
11.89 
(4.54) 
.847 Yes (n=12) 
13.17 (5.81) 
No (n=30) 
9.33 (3.30) 
.050 
 
 
Table 6: Comparison ICU LOS and adverse event (AG reopening) within each group 
 
  Cohort 1 (n=25) 
Mean (SD) 
P Cohort 2 (n=42) 
Mean (SD) 
P 
 
ICU LOS (in days) 
when AG reopened  
Yes 
(n=7)  
4.43 
(2.07) 
No 
(n=18) 
3.17 
(6.91) 
.643 Yes (n=12) 
4.25 (3.44) 
No (n=29) 
1.69 (2.19) 
.031 
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Figure 1: Framework for the Continual Improvement of Health Care, Batalden & Stoltz (1995) 
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